Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer Aβ species, which are more prone to aggregation [28]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“and, consequently, could be more pathogenic than shorter Aβ species”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [8]
In the citing paper
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer's disease (AD) (Haass and Selkoe, 2007).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Haass and Selkoe, 2007
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These and other findings led to the formal proposal of a hypothesis of disease in which excessive Aβ accumulation and deposition could trigger a complex downstream cascade that resulted in the symptoms of A”
ResultRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“In a similar manner, breakthrough discoveries of causative genes allowed the subsequent identification of aggregation-prone proteins in disorders such as amyotrophic lateral sclerosis (ALS”
ResultUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“More recently, TDP43 was found to be deposited in tau- and synuclein-negative inclusions in a disorder designated as frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) as well as in AL”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Shortly thereafter, a distinct APP missense mutation was found in a family with early-onset A”
Background
Cited by
Items 301–400 of 1,119
MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Maes, O., Chertkow, H., Wang, E., & Schipper, H. (2009) · Current Genomics · doi:10.2174/138920209788185252 · Cited by 214
“In familial AD, the ratio of A 42/A 40 specifically increases [15].”
BackgroundMysterious oligomerization of the amyloidogenic proteins
Uversky, V. N. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07721.x · Cited by 215
Binding of zinc(II) and copper(II) to the full‐length Alzheimer’s amyloid‐β peptide
Tõugu, V., Karafin, A., & Palumaa, P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05061.x · Cited by 216
Ahmad, A., Ali, T., Park, H. Y., Badshah, H., Rehman, S. U., & Kim, M. O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9795-4 · Cited by 216
“The finding that Aβ1–42 induces downregulation of the PI3K/Akt/GSK3β signaling pathway in the hippocampus of Aβ1–42-treated mice is consistent with previous reports that the inhibition of these signaling cascades contributes to Aβ1– 42-induced neurodegeneration and decreased neuronal survival [33, 45, 55].”
RetractedCheon, M., Chang, I., Mohanty, S., Luheshi, L. M., Dobson, C. M., Vendruscolo, M., & Favrin, G. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030173 · Cited by 215
“In this paper we investigate the early stages of the oligomerization process for two fragments (Ab16–22 and Ab25–35) of theAbpeptide, a key pathogenic agent inAlzheimer disease [21] by using all-atom computer simulations (see Methods) able to describe the essence of peptide aggregation reactions at the molecular level…”
Frenkel, D., Wilkinson, K., Zhao, L., Hickman, S. E., Means, T. K., Puckett, L., Farfara, D., Kingery, N. D., Weiner, H. L., & El Khoury, J. (2013) · Nature Communications · doi:10.1038/ncomms3030 · Cited by 214
“These soluble forms of A β (sA β ) include A β monomers or oligomers that remain soluble in aqueous buffers after high speed ultracentrifugation 9, 10 . sA β may start accumulating in the brain before formation of visible senile plaques. sA β is associated with cognitive dysfunction in transgenic…”
BackgroundYang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213
“For example, the broad transduction of the forebrain areas is a property that can be applied to treat Alzheimer’s disease, which causes neurodegeneration in forebrain areas [34].”
BackgroundLipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide
Gobbi, M., Re, F., Canovi, M., Beeg, M., Gregori, M., Sesana, S., Sonnino, S., Brogioli, D., Musicanti, C., Gasco, P., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.044 · Cited by 192
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
Inflammation in the early stages of neurodegenerative pathology
Khandelwal, P. J., Herman, A. M., & Moussa, C. E.-H. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.07.002 · Cited by 212
Chemical Fluorescent Probe for Detection of Aβ Oligomers
Teoh, C. L., Su, D., Sahu, S., Yun, S.-W., Drummond, E., Prelli, F., Lim, S., Cho, S., Ham, S., Wisniewski, T., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06190 · Cited by 209
Fang, Y.-S., Tsai, K.-J., Chang, Y.-J., Kao, P., Woods, R., Kuo, P.-H., Wu, C.-C., Liao, J.-Y., Chou, S.-C., Lin, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5824 · Cited by 211
Meilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210
“Axonal dystrophy, dendritic spine loss, and CSF NfL detection are exacerbated in PS2APP;Trem2 ko mice The elevated A 42:A 40 ratio and fibrillar A oligomers in PS2APP;Trem2 ko brains would seem to be detrimental for neuronal health since A 42 oligomers are commonly understood to be the more toxic form of A (Klein, 200…”
BackgroundHuntington’s disease: degradation of mutant huntingtin by autophagy
Sarkar, S., & Rubinsztein, D. C. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06562.x · Cited by 209
Amyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons
Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Shimoda, M., Matsuoka, M., & Aiso, S. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.105 · Cited by 194
Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., Hell, S. W., & Simons, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5345-07.2008 · Cited by 210
“A is liberated from the APP by the concerted action of two proteases, termed - and -secretase (Kao et al., 2004; Small and Gandy, 2006; Haass and Selkoe, 2007).”
BackgroundDomain Conformation of Tau Protein Studied by Solution Small-Angle X-ray Scattering
Mylonas, E., Hascher, A., Bernadó, P., Blackledge, M., Mandelkow, E., & Svergun, D. I. (2008) · Biochemistry · doi:10.1021/bi800900d · Cited by 218
“Alzheimer’s disease is the most common form of dementia among older people (1).”
BackgroundCheung, K.-H., Mei, L., Mak, D.-O. D., Hayashi, I., Iwatsubo, T., Kang, D. E., & Foskett, J. K. (2010) · Science Signaling · doi:10.1126/scisignal.2000818 · Cited by 209
Ion Channel Formation by Amyloid-β42 Oligomers but Not Amyloid-β40 in Cellular Membranes
Bode, D. C., Baker, M. D., & Viles, J. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762526 · Cited by 209
“Attention has shifted to a series of A (1– 42) oligomers ranging from 9 to 200 kDa that have been proven to be more toxic than monomeric and fibrillar forms of A (1– 42) (10, 11, 35, 36).”
BackgroundSingh, N., Haldar, S., Tripathi, A. K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4931 · Cited by 208
“Mutations in APP and presenilin genes 1 and 2 increase A b generation and are associated with the dominantly inherited form of AD, implicating A b as the principal cause of neuro-toxicity (184).”
Trinchese, F., Fa’, M., Liu, S., Zhang, H., Hidalgo, A., Schmidt, S. D., Yamaguchi, H., Yoshii, N., Mathews, P. M., Nixon, R. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34254 · Cited by 208
“trations as naturally secreted oligomers of Aβ (69).”
Habchi, J., Arosio, P., Perni, M., Costa, A. R., Yagi-Utsumi, M., Joshi, P., Chia, S., Cohen, S. I. A., Müller, M. B. D., Linse, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1501244 · Cited by 208
Naert, G., & Rivest, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0299-11.2011 · Cited by 207
“A can form different oligomeric assemblies, such as monomers, dimers, or A *56, to finally generate amyloid plaques (Lesné et al., 2006; Haass and Selkoe, 2007).”
BackgroundAlpha-secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential
Lichtenthaler, S. F. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07081.x · Cited by 207
Understanding Synapses: Past, Present, and Future
Südhof, T. C., & Malenka, R. C. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.011 · Cited by 207
Intramembrane Proteolysis by γ-Secretase
Steiner, H., Fluhrer, R., & Haass, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800010200 · Cited by 206
Self-citationThe structured core domain of αB-crystallin can prevent amyloid fibrillation and associated toxicity
Hochberg, G. K. A., Ecroyd, H., Liu, C., Cox, D., Cascio, D., Sawaya, M. R., Collier, M. P., Stroud, J., Carver, J. A., Baldwin, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322673111 · Cited by 206
Lipid Rafts and Alzheimer’s Disease: Protein-Lipid Interactions and Perturbation of Signaling
Hicks, D. A., Nalivaeva, N. N., & Turner, A. J. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00189 · Cited by 206
“…cascade hypothesis, it is the Aβ which is principally responsible for many of the pathological features of the disease (Hardy and Higgins, 1992; Sakono and Zako, 2010) with Aβ oligomers representing the most toxic species (Haass and Selkoe, 2007; Walsh and Selkoe, 2007; Sakono and Zako, 2010).”
BackgroundHladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Role of EGFR in the Nervous System
Romano, R., & Bucci, C. (2020) · Cells · doi:10.3390/cells9081887 · Cited by 202
Powers, E. T., & Powers, D. L. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.117168 · Cited by 204
Wobst, H. J., Sharma, A., Diamond, M. I., Wanker, E. E., & Bieschke, J. (2015) · FEBS Letters · doi:10.1016/j.febslet.2014.11.026 · Cited by 203
Mitochondrial glutathione: Features, regulation and role in disease
Marí, M., Morales, A., Colell, A., García-Ruiz, C., Kaplowitz, N., & Fernández-Checa, J. C. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.10.018 · Cited by 204
Taylor, C. J., Ireland, D. R., Ballagh, I., Bourne, K., Marechal, N. M., Turner, P. R., Bilkey, D. K., Tate, W. P., & Abraham, W. C. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.011 · Cited by 203
“One of the earliest physiological alterations of pathogenic consequence is an intracellular accumulation of soluble amyloid-β (Aβ), generated by altered processing of the parent amyloid precursor protein (APP) by β- and γ-secretases (Wirths et al., 2004; Haass and Selkoe, 2007).”
BackgroundMannini, B., Mulvihill, E., Sgromo, C., Cascella, R., Khodarahmi, R., Ramazzotti, M., Dobson, C. M., Cecchi, C., & Chiti, F. (2014) · ACS Chemical Biology · doi:10.1021/cb500505m · Cited by 204
Vanillic acid attenuates Aβ1-42-induced oxidative stress and cognitive impairment in mice
Amin, F. U., Shah, S. A., & Kim, M. O. (2017) · Scientific Reports · doi:10.1038/srep40753 · Cited by 204
Bharadwaj, P., Wijesekara, N., Liyanapathirana, M., Newsholme, P., Ittner, L., Fraser, P., & Verdile, G. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161192 · Cited by 202
“Growing evidence suggests that smaller intermediate structures, known as oligomers are the main cytotoxic agents that correlate with disease progression [85].”
Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide
Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 225
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
“The pathogenic character of A has given origin to the “amyloid hypothesis” that states that the formation and deposition of small peptides of A forms long insoluble amyloid fibrils, which accumulate in senile plaques [24] in critical regions of the brain, leading to the onset and progression of AD [26] which in the lo…”
BackgroundInfluentialBritschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201
Regulation of Amyloid Precursor Protein Processing by the Beclin 1 Complex
Jaeger, P. A., Pickford, F., Sun, C.-H., Lucin, K. M., Masliah, E., & Wyss-Coray, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011102 · Cited by 200
“characterized pathologically by the presence of extracellular beta amyloid (Ab) assemblies called plaques [1,2], and intracellular accumulation of Ab [3] and tau [4].”
BackgroundChen, W.-T., Liao, Y.-H., Yu, H.-M., Cheng, I. H., & Chen, Y.-R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177246 · Cited by 199
How is protein aggregation in amyloidogenic diseases modulated by biological membranes?
Aisenbrey, C., Borowik, T., Byström, R., Bokvist, M., Lindström, F., Misiak, H., Sani, M.-A., & Gröbner, G. (2008) · European Biophysics Journal · doi:10.1007/s00249-007-0237-0 · Cited by 200
“The APP protein itself is a type-I transmembrane protein whose dimerization in membranes might play a pivotal role in its breakdown into A (Scheuermann et al. 2001; Haass and Selkoe 2007 ).”
BackgroundInfluentialDetection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer’s Disease
Salvadores, N., Shahnawaz, M., Scarpini, E., Tagliavini, F., & Soto, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.031 · Cited by 197
“Recent compelling evidence indicates that the formation of misfolded Ab oligomersmight be a critical event in AD pathogenesis (Walsh and Selkoe, 2007; Haass and Selkoe, 2007; Glabe and Kayed, 2006; Klein et al., 2004).”
BackgroundOligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism
Berman, D. E., Dall'Armi, C., Voronov, S. V., McIntire, L. B. J., Zhang, H., Moore, A. Z., Staniszewski, A., Arancio, O., Kim, T.-W., & Di Paolo, G. (2008) · Nature Neuroscience · doi:10.1038/nn.2100 · Cited by 199
“Aβ peptide is produced by the sequential proteolytic cleavage of amyloid precursor protein (APP) by the membrane-bound proteases β- and γ-secretase”
BackgroundHudry, E., Van Dam, D., Kulik, W., De Deyn, P. P., Stet, F. S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougnères, P., Aubourg, P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.175 · Cited by 198
Liposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198
Rajan, R., Ahmed, S., Sharma, N., Kumar, N., Debas, A., & Matsumura, K. (2021) · Materials Advances · doi:10.1039/d0ma00760a · Cited by 196
Crosstalk Between Calcium and Redox Signaling: From Molecular Mechanisms to Health Implications
Hidalgo, C., & Donoso, P. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1886 · Cited by 197
“These include disruption of calcium homeostasis by A ̇ oligomer-induced calcium-conducting pores in neuronal membranes (204, 361), or neurotoxic effects due to formation of intermediate A ̇ oligomers that accumulate in brain tissue of affected individuals (150).”
Structural Properties of Pore-Forming Oligomers of α-Synuclein
Kim, H.-Y., Cho, M.-K., Kumar, A., Maier, E., Siebenhaar, C., Becker, S., Fernandez, C. O., Lashuel, H. A., Benz, R., Lange, A., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9077599 · Cited by 196
Mitochondrial Dysfunction: The First Domino in Brain Aging and Alzheimer's Disease?
Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., Strosznajder, J. B., Eckert, A., & Müller, W. E. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1763 · Cited by 195
Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease
Miller, M. C., Tavares, R., Johanson, C. E., Hovanesian, V., Donahue, J. E., Gonzalez, L., Silverberg, G. D., & Stopa, E. G. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.124 · Cited by 194
“INTRODUCTION Amyloid-β peptide (Aβ) burden is a hallmark feature of Alzheimer’s disease (AD) [Wisniewski et al. 1997; Hardy 2006; Deane and Zlokovic 2007; Haass and Selkoe 2007].”
BackgroundAlzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170819 · Cited by 194
“According to the latest version of the amyloid cascade hypothesis [7], the pathological scenario of AD identifies the soluble small aggregates of A , A Os, as the main species responsible for the neuronal dysfunction [8, 9], and this concept has been extended to all the other protein misfolding disorders.”
BackgroundAutophagy in Neuroprotection and Neurodegeneration: A Question of Balance
Cherra 3rd, S. J., & Chu, C. T. (2008) · Future Neurology · doi:10.2217/14796708.3.3.309 · Cited by 192
“Improvement in motor symptoms [7] could also be explained by reduction in levels of toxic soluble oligomers and protofibrils [26,27].”
BackgroundCoarse-grained models for protein aggregation
Wu, C., & Shea, J.-E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.02.002 · Cited by 192
The duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 190
“Subse-quently, C99 is further cleaved by γ-secretase, resulting in the release of Aβ peptides [104], including the more common form, Aβ40, and the more toxic form, Aβ42 [105–107].”
BackgroundAmyloid efflux transporter expression at the blood-brain barrier declines in normal aging
Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f46e25 · Cited by 191
Epidermal growth factor receptor is a preferred target for treating Amyloid-β–induced memory loss
Wang, L., Chiang, H.-C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., & Zhong, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208011109 · Cited by 190
“It is known that Aβ oligomers are capable of disrupting long-term synaptic plasticity (1) and the downstream signaling pathways of EGFR, such as PI3-kinase and Ras, which are important in regulating long-term synaptic plasticity (17, 37, 43).”
BackgroundBourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bezard, E., Dehay, B., & Tsarbopoulos, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 185
“potentiation, and finally resulting in neurodegeneration (Haass and Selkoe, 2007; Selkoe, 1999; Shankar et al., 2008; Walsh and Selkoe, 2004).”
BackgroundJimenez, S., Torres, M., Vizuete, M., Sanchez-Varo, R., Sanchez-Mejias, E., Trujillo-Estrada, L., Carmona-Cuenca, I., Caballero, C., Ruano, D., Gutierrez, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209718 · Cited by 188
Effects of Grape Seed-derived Polyphenols on Amyloid β-Protein Self-assembly and Cytotoxicity*
Ono, K., Condron, M. M., Ho, L., Wang, J., Zhao, W., Pasinetti, G. M., & Teplow, D. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806154200 · Cited by 188
Amyloid structures: much more than just a cross-β fold
Gallardo, R., Ranson, N. A., & Radford, S. E. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.09.001 · Cited by 189
“We also need to remember that oligomers also play a key role in amyloid disease [14,15], yet structurally characterising these species remains a hugely challenging task in vitro, and is not possible currently in vivo.”
Jang, H., Zheng, J., & Nussinov, R. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.110148 · Cited by 187
Liu, W., Liu, C., Zhu, J., Shu, P., Yin, B., Gong, Y., Qiang, B., Yuan, J., & Peng, X. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.034 · Cited by 188
“It is the most common form of dementia (Bertram and Tanzi, 2008; Hardy and Selkoe, 2002; Harris et al., 2003).”
BackgroundRaskin, J., Cummings, J., Hardy, J., Schuh, K., & Dean, R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150701103107 · Cited by 188
“Soluble Aβ oligomers appear to be neurotoxic, inducing synaptic dysfunction [31].”
InfluentialCrucial role of nonspecific interactions in amyloid nucleation
Šarić, A., Chebaro, Y. C., Knowles, T. P. J., & Frenkel, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410159111 · Cited by 186
“[32] Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide.”
BackgroundExcessive aggregation of membrane proteins in the Martini model
Javanainen, M., Martinez-Seara, H., & Vattulainen, I. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187936 · Cited by 184
Fradinger, E. A., Monien, B. H., Urbanc, B., Lomakin, A., Tan, M., Li, H., Spring, S. M., Condron, M. M., Cruz, L., Xie, C.-W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807163105 · Cited by 186
“Synaptic failure has been postulated to be the primary event leading to the development of AD (5, 29).”
BackgroundOut-of-register β-sheets suggest a pathway to toxic amyloid aggregates
Liu, C., Zhao, M., Jiang, L., Cheng, P.-N., Park, J., Sawaya, M. R., Pensalfini, A., Gou, D., Berk, A. J., Glabe, C. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218792109 · Cited by 186
“(1998) Propagating structure of Alzheimer’s beta-amyloid(10-35)”
BackgroundInfluentialSingh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 186
Di Scala, C., Yahi, N., Boutemeur, S., Flores, A., Rodriguez, L., Chahinian, H., & Fantini, J. (2016) · Scientific Reports · doi:10.1038/srep28781 · Cited by 186
Lee, S., Zheng, X., Krishnamoorthy, J., Savelieff, M. G., Park, H. M., Brender, J. R., Kim, J. H., Derrick, J. S., Kochi, A., Lee, H. J., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja409801p · Cited by 182
Docosahexaenoic acid: one molecule diverse functions
Hashimoto, M., Hossain, S., Al Mamun, A., Matsuzaki, K., & Arai, H. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2016.1207153 · Cited by 184
“Recent findings suggest that soluble Ab oligomers, rather than matured-fibrils, correlate intensely with neuronal dysfunction, damage and AD symptoms [130].”
BackgroundThe impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185
Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 185
The role of microRNAs in neurodegenerative diseases: a review
Li, S., Lei, Z., & Sun, T. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09761-x · Cited by 183
“The root cause of this protein disease and its associated neurodegeneration is a metabolic disorder (Haass and Selkoe 2007).”
BackgroundRecognition of the Amyloid Precursor Protein by Human gamma-secretase: 6iyc
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6iyc/pdb · Cited by 185
Zhang, Y., Kurup, P., Xu, J., Carty, N., Fernandez, S. M., Nygaard, H. B., Pittenger, C., Greengard, P., Strittmatter, S. M., Nairn, A. C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013543107 · Cited by 184
“Considerable evidence implicates β amyloid (Aβ) peptides in the pathophysiology of AD (1).”
BackgroundMetal ions as modulators of protein conformation and misfolding in neurodegeneration
Leal, S. S., Botelho, H. M., & Gomes, C. M. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.004 · Cited by 183
MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1
Zhu, H.-C., Wang, L.-M., Wang, M., Song, B., Tan, S., Teng, J.-F., & Duan, D.-X. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.05.018 · Cited by 204
Deane, R., Sagare, A., & Zlokovic, B. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705487 · Cited by 183
Suppression of Alzheimer's Disease-Related Phenotypes by Expression of Heat Shock Protein 70 in Mice
Hoshino, T., Murao, N., Namba, T., Takehara, M., Adachi, H., Katsuno, M., Sobue, G., Matsushima, T., Suzuki, T., & Mizushima, T. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5478-10.2011 · Cited by 183
“However, monomeric A easily self-assembles to form oligomers, protofibrils, and fibrils, and it is now believed that less aggregated forms of A , such as oligomers and protofibrils, are more important than the highly aggregated forms (Haass and Selkoe, 2007).”
BackgroundFigueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C. V., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 183
“Although A Os are increasingly recognized as key mediators of synaptic and cognitive dysfunction in Alzheimer’s disease (AD) (Ferreira et al., 2007; Haass and Selkoe, 2007; Ferreira and Klein, 2011; Benilova et al., 2012; Selkoe, 2012), the molecular identity and the mechanisms by which oligomers…”
BackgroundLiu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., Wang, M., Sierks, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3952-08.2009 · Cited by 182
“A recent study suggested that levels of oligomeric forms of A 1– 42, rather than monomers or A fibrils, most closely correlate with cognitive dysfunction in animal models of AD (Haass and Selkoe, 2007).”
BackgroundAlzheimer’s Disease: The Link Between Amyloid-β and Neurovascular Dysfunction
Solis, Hascup, K. N., & Hascup, E. R. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200473 · Cited by 178
“Altered neurotransmission and the subsequent neurodegeneration are hypothesized to contribute to the cognitive and behavioral decline observed in AD [28, 29].”
Kumar, S., & Walter, J. (2011) · Aging · doi:10.18632/aging.100362 · Cited by 180
Oliveira, T. G., Chan, R. B., Tian, H., Laredo, M., Shui, G., Staniszewski, A., Zhang, H., Wang, L., Kim, T.-W., Duff, K. E., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3317-10.2010 · Cited by 179
“Importantly, elevation of soluble A oligomers strongly correlates with cognitive decline, consistent with the synaptotoxic properties exhibited by these peptides in various systems (Haass and Selkoe, 2007).”
BackgroundInfluentialLemkul, J. A., & Bevan, D. R. (2010) · Biochemistry · doi:10.1021/bi1000855 · Cited by 179
Common mechanism unites membrane poration by amyloid and antimicrobial peptides
Last, N. B., & Miranker, A. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219059110 · Cited by 179
“Toxic amyloid oligomers, such as those made by islet amyloid polypeptide (IAPP), amyloid-β (Aβ), and α-synuclein, have also been shown to formmembrane pores that are capable of contributing to cell death in amyloid disease (2, 3).”
Backgroundβ-Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure
Parodi, J., Sepúlveda, F. J., Roa, J., Opazo, C., Inestrosa, N. C., & Aguayo, L. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030023 · Cited by 179
Loureiro, J. A., Gomes, B., Fricker, G., Coelho, M. A. N., Rocha, S., & Pereira, M. C. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.04.041 · Cited by 179
Gold‐Nanoparticle‐Based Multifunctional Amyloid‐β Inhibitor against Alzheimer’s Disease
Gao, N., Sun, H., Dong, K., Ren, J., & Qu, X. (2015) · Chemistry – A European Journal · doi:10.1002/chem.201404562 · Cited by 177
Hureau, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.037 · Cited by 178
Gu, Z., Liu, W., & Yan, Z. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806508200 · Cited by 176
Mesa-Herrera, F., Taoro-González, L., Valdés-Baizabal, C., Diaz, M., & Marín, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153810 · Cited by 176
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C., & Initiative, A. T. A. D. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003956 · Cited by 175
“For instance, Aß toxicity has been causally associated with brain oxidative stress [14], [18], mitochondrial dysfunction [18], synapse and spine loss [13], widespread neuronal dysfunction and cell death [12], synaptic plasticity and memory impairment [16], [17].”
BackgroundAβ Toxicity in Alzheimer's Disease
Cavallucci, V., D’Amelio, M., & Cecconi, F. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8251-3 · Cited by 177
“and AD subjects [90, 91].”
Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts
Bhattacharyya, R., Barren, C., & Kovacs, D. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4704-12.2013 · Cited by 171
“It is well known that both AD and aging are characterized by elevated A accumulation, at a much higher degree in the brains of patients affected by AD than during normal aging (Price et al., 1992; Haass and Selkoe, 2007; Reddy and Beal, 2008).”
Huntington's disease: The current state of research with peripheral tissues
Sassone, J., Colciago, C., Cislaghi, G., Silani, V., & Ciammola, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.012 · Cited by 175
Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., Lefebvre, T., Sprenger, F., Wirths, O., Zweckstetter, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1129-2 · Cited by 175
“1 3 There is increasing evidence that the primary insult in AD is caused by oligomeric species derived from fulllength Aβ1-42 impairing synaptic functions [14, 67].”
Background
Metadata
- Authors
- Haass, C., & Selkoe, D. J.
- Affiliations
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 101-112
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1980825524
- Cited by
- 4,744
- References
- 135
- Citations by year
- 2026: 135 · 2025: 171 · 2024: 165 · 2023: 170 · 2022: 195 · 2021: 239 · 2020: 273 · 2019: 247 · 2018: 276 · 2017: 290 · 2016: 331 · 2015: 313 · 2014: 285 · 2013: 307 · 2012: 327
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurodegeneration, protein misfolding, protein aggregation, synaptic dysfunction, synaptic plasticity, Parkinson's disease, Huntington's disease, prion disease, neuronal dysfunction
- MeSH terms
- Alzheimer Disease, Cell Membrane, Humans, Memory Disorders, Models, Biological, Nerve Degeneration, Solubility, Synapses, Signal Transduction, Amyloid beta-Peptides, Protein Folding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.